Macrophage colony-stimulating factor in murine candidiasis

Serum and tissue levels during infection and protective effect of exogenous administration

E. Cenci, A. Bartocci, P. Puccetti, S. Mocci, E. R. Stanley, F. Bistoni

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Serum and tissue concentrations of the macrophage-specific colony-stimulating factor (CSF-1) and the number of CSF-1-responsive cells in bone marrow were investigated in mice chronically infected with a low-virulence strain of the opportunistic zoopathogenic yeast Candida albicans. CSF-1 levels in serum, brain, kidney, liver, and lung were significantly increased shortly after infection and remained elevated during the 2 weeks preceding the onset of specific T cell-dependent immunity. The number of monocytic precursor cells was also increased in the bone marrow of infected mice. When macrophages from naive donors were exposed in vitro to purified murine CSF-1, their anticandidal activity in vitro appeared to be enhanced. CSF-1 was also administered in vivo to prospective recipients of a lethal C. albicans challenge. The results showed that the factor could effectively potentiate the animals' resistance to the yeast, as shown by increased survival times and reduced recovery of viable C. albicans from the organs of the CSF-1-treated mice. Therefore, the present data suggest that CSF-1 is likely to contribute to early resistance to fungal infection and could be successfully exploited in experimental models of antifungal immunotherapy.

Original languageEnglish (US)
Pages (from-to)868-872
Number of pages5
JournalInfection and Immunity
Volume59
Issue number3
StatePublished - 1991
Externally publishedYes

Fingerprint

Macrophage Colony-Stimulating Factor
Candidiasis
Infection
Serum
Candida albicans
Yeasts
Mycoses
Bone Marrow Cells
Immunotherapy
Virulence
Immunity
Theoretical Models
Bone Marrow
Macrophages
T-Lymphocytes
Kidney
Lung
Liver
Brain

ASJC Scopus subject areas

  • Immunology

Cite this

Macrophage colony-stimulating factor in murine candidiasis : Serum and tissue levels during infection and protective effect of exogenous administration. / Cenci, E.; Bartocci, A.; Puccetti, P.; Mocci, S.; Stanley, E. R.; Bistoni, F.

In: Infection and Immunity, Vol. 59, No. 3, 1991, p. 868-872.

Research output: Contribution to journalArticle

Cenci, E. ; Bartocci, A. ; Puccetti, P. ; Mocci, S. ; Stanley, E. R. ; Bistoni, F. / Macrophage colony-stimulating factor in murine candidiasis : Serum and tissue levels during infection and protective effect of exogenous administration. In: Infection and Immunity. 1991 ; Vol. 59, No. 3. pp. 868-872.
@article{f879e9501e1c435fbd9671690114f3f4,
title = "Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration",
abstract = "Serum and tissue concentrations of the macrophage-specific colony-stimulating factor (CSF-1) and the number of CSF-1-responsive cells in bone marrow were investigated in mice chronically infected with a low-virulence strain of the opportunistic zoopathogenic yeast Candida albicans. CSF-1 levels in serum, brain, kidney, liver, and lung were significantly increased shortly after infection and remained elevated during the 2 weeks preceding the onset of specific T cell-dependent immunity. The number of monocytic precursor cells was also increased in the bone marrow of infected mice. When macrophages from naive donors were exposed in vitro to purified murine CSF-1, their anticandidal activity in vitro appeared to be enhanced. CSF-1 was also administered in vivo to prospective recipients of a lethal C. albicans challenge. The results showed that the factor could effectively potentiate the animals' resistance to the yeast, as shown by increased survival times and reduced recovery of viable C. albicans from the organs of the CSF-1-treated mice. Therefore, the present data suggest that CSF-1 is likely to contribute to early resistance to fungal infection and could be successfully exploited in experimental models of antifungal immunotherapy.",
author = "E. Cenci and A. Bartocci and P. Puccetti and S. Mocci and Stanley, {E. R.} and F. Bistoni",
year = "1991",
language = "English (US)",
volume = "59",
pages = "868--872",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Macrophage colony-stimulating factor in murine candidiasis

T2 - Serum and tissue levels during infection and protective effect of exogenous administration

AU - Cenci, E.

AU - Bartocci, A.

AU - Puccetti, P.

AU - Mocci, S.

AU - Stanley, E. R.

AU - Bistoni, F.

PY - 1991

Y1 - 1991

N2 - Serum and tissue concentrations of the macrophage-specific colony-stimulating factor (CSF-1) and the number of CSF-1-responsive cells in bone marrow were investigated in mice chronically infected with a low-virulence strain of the opportunistic zoopathogenic yeast Candida albicans. CSF-1 levels in serum, brain, kidney, liver, and lung were significantly increased shortly after infection and remained elevated during the 2 weeks preceding the onset of specific T cell-dependent immunity. The number of monocytic precursor cells was also increased in the bone marrow of infected mice. When macrophages from naive donors were exposed in vitro to purified murine CSF-1, their anticandidal activity in vitro appeared to be enhanced. CSF-1 was also administered in vivo to prospective recipients of a lethal C. albicans challenge. The results showed that the factor could effectively potentiate the animals' resistance to the yeast, as shown by increased survival times and reduced recovery of viable C. albicans from the organs of the CSF-1-treated mice. Therefore, the present data suggest that CSF-1 is likely to contribute to early resistance to fungal infection and could be successfully exploited in experimental models of antifungal immunotherapy.

AB - Serum and tissue concentrations of the macrophage-specific colony-stimulating factor (CSF-1) and the number of CSF-1-responsive cells in bone marrow were investigated in mice chronically infected with a low-virulence strain of the opportunistic zoopathogenic yeast Candida albicans. CSF-1 levels in serum, brain, kidney, liver, and lung were significantly increased shortly after infection and remained elevated during the 2 weeks preceding the onset of specific T cell-dependent immunity. The number of monocytic precursor cells was also increased in the bone marrow of infected mice. When macrophages from naive donors were exposed in vitro to purified murine CSF-1, their anticandidal activity in vitro appeared to be enhanced. CSF-1 was also administered in vivo to prospective recipients of a lethal C. albicans challenge. The results showed that the factor could effectively potentiate the animals' resistance to the yeast, as shown by increased survival times and reduced recovery of viable C. albicans from the organs of the CSF-1-treated mice. Therefore, the present data suggest that CSF-1 is likely to contribute to early resistance to fungal infection and could be successfully exploited in experimental models of antifungal immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0026030823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026030823&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 868

EP - 872

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 3

ER -